Uytengsu-Hamilton 22q11 Neuropsychiatry Research Program

The Stanford Maternal and Child Health Research Institute (MCHRI) Uytengsu-Hamilton 22q11 Neuropsychiatry Research Program aims to promote research to improve the neurocognitive outcomes and behavioral symptoms of 22q11.2 Deletion Syndrome with immediate (within 5 years) and long-term impact. 

22q11.2 Deletion Syndrome (22q11.2DS) is a genetic disorder caused by a deletion on chromosome 22 (at location 22q11.2). The prevalence of 22q11.2DS is estimated to be 1:2000 to 1:4000 and the disorder is associated with a broad spectrum of symptoms including immune dysfunction, congenital heart disease, palatal abnormalities and endocrine dysfunction. Children with 22q11.2DS are at increased risk for developmental delay, learning disabilities, neurodevelopmental and neuropsychiatric disorders including attention-deficit / hyperactivity disorder (ADHD), autism spectrum disorder (ASD), anxiety and schizophrenia.